Anadis Licenses Antibody Technologies From ImmuCell: Includes E. Coli And C. Difficile

Anadis Limited (ASX: ANX), an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced that it had signed a final agreement with ImmuCell Corporation (NASDAQ Capital Market: ICCC), a biotechnology company headquartered in Portland, Maine, USA.

More: continued here

Filed under: Medical Devices on March 15th, 2008